<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02988050</url>
  </required_header>
  <id_info>
    <org_study_id>MenoufiaU2016</org_study_id>
    <nct_id>NCT02988050</nct_id>
  </id_info>
  <brief_title>Conscious Sedation for Epilepsy Surgery</brief_title>
  <official_title>Propofol-dexmedetomidine Versus Propofol-remifentanil Conscious Sedation for Awake Craniotomy During Epilepsy Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Menoufia University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Menoufia University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Sixty patients were randomly allocated into two groups, group PD and group PR, thirty&#xD;
      patients in each group. Patients in PD group received propofol and dexmedetomidine&#xD;
      intravenous infusion and patients in PR group received propofol and remifentanil intravenous&#xD;
      infusion. Sedation score and patients' satisfaction, surgeon satisfaction, heart rate, mean&#xD;
      arterial blood pressure, oxygen saturation, and side effects such as respiratory depression,&#xD;
      nausea, vomiting, airway obstruction, and oxygen desaturation were recorded.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      After approval from the ethics committee of Menoufia University Hospitals and informed&#xD;
      written consent, the present study was conducted on sixty patients of both sexes. Patients'&#xD;
      age was between 18-50 years, American society of anesthesiologists (ASA) I and II and&#xD;
      scheduled for awake craniotomy for treatment of epilepsy. Exclusion criteria included&#xD;
      patients with history of allergy to any of the drugs used for the study, patients with&#xD;
      alcohol or substance abuse, pregnant females, patients with mental instability, morbid obese&#xD;
      patients, and patients with liver, kidney, or cardiac comorbidities.&#xD;
&#xD;
      Patients were randomly allocated using computerized software into two groups, thirty patients&#xD;
      in each group to receive intra-operative either propofol-dexmedetomidine (PD group) or&#xD;
      propofol-remifentanil (PR group) intravenous infusion. All patients received their routine&#xD;
      treatment for epilepsy at their scheduled time before surgery. All patients were fully&#xD;
      monitored intra-operatively for heart rate, non-invasive blood pressure, oxygen saturation,&#xD;
      respiratory rate, and bi-spectral index (BIS). Oxygen was supplied to all patients via nasal&#xD;
      cannula peri-operatively.&#xD;
&#xD;
      Anaesthesia was achieved by regional scalp block and IV sedation. Regional blockade of the&#xD;
      scalp was performed using bupivacaine 0.5% and 2% lidocaine with epinephrine 1/200.000. The&#xD;
      branches of the cranial nerves blocked were supratrochlear, supraorbital, auriculotemporal,&#xD;
      greater and lesser occipital, great auricular, zygomatic, and infraorbital nerves.&#xD;
      Supplemental local anesthetic solution was used to infiltrate along the incision lines prior&#xD;
      to skin incision. During craniotomy, a mixture of 0.25% bupivacaine and lidocaine1% without&#xD;
      epinephrine was used to anesthetize the dura mater. The maximum dose of lidocaine used did&#xD;
      not exceed 4.5 mg kg -1 and for bupivacaine 3 mg kg -1.&#xD;
&#xD;
      All patients received propofol 1% with a starting intravenous infusion dose of 250 μg kg-1&#xD;
      min-1 for 15 min and then basal infusion dose at 50 μg kg-1min-1. Sedation was achieved for&#xD;
      group PD by a combination of propofol and dexmedetomidine with a starting infusion dose of&#xD;
      1ug kg-1 hr -1 for 15 min, and then titrated down to 0.2μ g kg-1 hr-1.&#xD;
&#xD;
      In PR group, IV sedation was achieved by a combination of propofol and remifentanil at an&#xD;
      initial bolus dose of 0.5 μg.kg-1 over 60 seconds and then a basal infusion of 0.1μg kg-1&#xD;
      min1. Insufficient sedation in both groups was treated with boluses of 250 μg kg-1 propofol.&#xD;
      The total amount of propofol used in both groups was recorded.&#xD;
&#xD;
      Sedation was assessed using Ramsay sedation score.6 Patient scored (1) if was anxious,&#xD;
      agitated, or restless. Patient scored (2) if was cooperative, oriented and tranquil. Score 3&#xD;
      was for patients responded to command only. Score (4) for patients exhibited brisk respond to&#xD;
      light glabellar tap or loud auditory stimulus. Score (5) for patients exhibited a sluggish&#xD;
      response to light glabellar tap or loud auditory stimulus. Score (6) was for patients&#xD;
      exhibited no response. Score (1) means inadequate sedation, score (2 to 4) means acceptable&#xD;
      sedation, and score (5) or (6) means excessive sedation. Bi-spectral index (BIS) was&#xD;
      connected to all patients and recorded every half an hour intra-operatively until the end&#xD;
      surgery.&#xD;
&#xD;
      For intraoperative neurophysiologic monitoring propofol infusion was stopped for 15 minutes&#xD;
      to avoid interference.&#xD;
&#xD;
      Side effects such as respiratory depression (respiratory rate less than 8/min), nausea,&#xD;
      vomiting, airway obstruction, oxygen desaturation (oxygen saturation less than 90 %), and&#xD;
      hypotension or hypertension (20% decrease or increase from the base line) were recorded. In&#xD;
      case of apnea, respiratory depression, oxygen desaturation, and airway obstruction or&#xD;
      hypotension all infusions were stopped until normalization and then the infusion resumed at&#xD;
      half the basal rate. Vomiting was treated with 4mg intravenous ondansetron and the total&#xD;
      ondansetron consumption was recorded for both groups.&#xD;
&#xD;
      If intraoperative convulsions occurred at any time IV thiopental sodium was given at a dose&#xD;
      1-2 mg kg-1. General anaesthesia was given if indicated and the patient was removed from the&#xD;
      study. The excluded patients were replaced according to the schedule of randomization to keep&#xD;
      the number of the two groups. Indications for general anesthesia were failure of the regional&#xD;
      block, marked patient irritability, severe airway obstruction required intubation,&#xD;
      uncontrolled convulsions, and haemodynamic instability.&#xD;
&#xD;
      Patient's satisfaction was recorded using a score ranging from 0 not satisfied and 10 totally&#xD;
      satisfied. Surgeon satisfaction regarding the operative conditions and the anesthetic&#xD;
      technique was recorded as 0 very bad operative conditions, 1 moderate, and 2 good.&#xD;
&#xD;
      Statistical analysis Sample size calculation was calculated using graphed instant statistics&#xD;
      version 3. Based on previous research, dexmedetomidine was expected to produce a decrease in&#xD;
      the heart rate by about 10 beats /minute with a standard deviation of 10 and by choosing 5%&#xD;
      level of significance and power of 90% the calculated sample size was 22 so that, the sample&#xD;
      size used in the study was 30 patients to ensure reliable results.&#xD;
&#xD;
      Data were analyzed using SPSS 19 program. Student t-test was used for comparing data between&#xD;
      the two groups. Chi square test was used to compare the incidence of side effects. P value of&#xD;
      less than 0.05 was considered to be statistically significant.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2013</start_date>
  <completion_date type="Actual">April 2016</completion_date>
  <primary_completion_date type="Actual">February 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Patients Satisfaction</measure>
    <time_frame>1 hour after the operation</time_frame>
    <description>Patient's satisfaction was recorded using a score ranging from 0 for not satisfied to 10 for totally satisfied.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Epilepsy</condition>
  <arm_group>
    <arm_group_label>Propofol-dexmedetomidine</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Propofol-dexmedetomidine Bupivacaine; Lidocaine (local anaesthetics) Epinephrine (with local anaesthetics for skin infiltration)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Propofol-remifentanil</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Propofol-remifentanil Bupivacaine; Lidocaine Epinephrine (with local anaesthetics for skin infiltration)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Remifentanil</intervention_name>
    <description>Remifentanil used for conscious sedation.</description>
    <arm_group_label>Propofol-remifentanil</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexmedetomidine</intervention_name>
    <description>Dexmedetomidine used for conscious sedation.</description>
    <arm_group_label>Propofol-dexmedetomidine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Propofol</intervention_name>
    <description>Used for conscious sedation.</description>
    <arm_group_label>Propofol-dexmedetomidine</arm_group_label>
    <arm_group_label>Propofol-remifentanil</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bupivacaine</intervention_name>
    <description>Local anaesthetics</description>
    <arm_group_label>Propofol-dexmedetomidine</arm_group_label>
    <arm_group_label>Propofol-remifentanil</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lidocaine</intervention_name>
    <description>Local anaesthetic</description>
    <arm_group_label>Propofol-dexmedetomidine</arm_group_label>
    <arm_group_label>Propofol-remifentanil</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Epinephrine</intervention_name>
    <description>With local anaesthetic for skin infiltration.</description>
    <arm_group_label>Propofol-dexmedetomidine</arm_group_label>
    <arm_group_label>Propofol-remifentanil</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients require conscious sedation for epilepsy surgery&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients refusal, allergy to drugs used, and uncooperative patients.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>November 28, 2016</study_first_submitted>
  <study_first_submitted_qc>December 8, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 9, 2016</study_first_posted>
  <results_first_submitted>August 10, 2020</results_first_submitted>
  <results_first_submitted_qc>September 16, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">October 9, 2020</results_first_posted>
  <last_update_submitted>September 16, 2020</last_update_submitted>
  <last_update_submitted_qc>September 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Menoufia University</investigator_affiliation>
    <investigator_full_name>Dr Ezzeldin Ibrahim</investigator_full_name>
    <investigator_title>Assistant Professor in anaesthesia, intensive care, and pain medicine</investigator_title>
  </responsible_party>
  <keyword>Epilepsy Surgery</keyword>
  <keyword>Conscious sedation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epilepsy</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lidocaine</mesh_term>
    <mesh_term>Epinephrine</mesh_term>
    <mesh_term>Dexmedetomidine</mesh_term>
    <mesh_term>Remifentanil</mesh_term>
    <mesh_term>Bupivacaine</mesh_term>
    <mesh_term>Propofol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Patients were excluded if they refused to be included in the study.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Propofol-dexmedetomidine</title>
          <description>Propofol-dexmedetomidine Bupivacaine; Lidocaine (local anaesthetics) Epinephrine (with local anaesthetics for skin infiltration)&#xD;
Dexmedetomidine: Dexmedetomidine used for conscious sedation.&#xD;
Propofol: Used for conscious sedation.&#xD;
Bupivacaine: Local anaesthetics&#xD;
Lidocaine: Local anaesthetic&#xD;
Epinephrine: With local anaesthetic for skin infiltration.</description>
        </group>
        <group group_id="P2">
          <title>Propofol-remifentanil</title>
          <description>Propofol-remifentanil Bupivacaine; Lidocaine Epinephrine (with local anaesthetics for skin infiltration)&#xD;
Remifentanil: Remifentanil used for conscious sedation.&#xD;
Propofol: Used for conscious sedation.&#xD;
Bupivacaine: Local anaesthetics&#xD;
Lidocaine: Local anaesthetic&#xD;
Epinephrine: With local anaesthetic for skin infiltration.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Propofol-dexmedetomidine</title>
          <description>Propofol-dexmedetomidine Bupivacaine; Lidocaine (local anaesthetics) Epinephrine (with local anaesthetics for skin infiltration)&#xD;
Dexmedetomidine: Dexmedetomidine used for conscious sedation.&#xD;
Propofol: Used for conscious sedation.&#xD;
Bupivacaine: Local anaesthetics&#xD;
Lidocaine: Local anaesthetic&#xD;
Epinephrine: With local anaesthetic for skin infiltration.</description>
        </group>
        <group group_id="B2">
          <title>Propofol-remifentanil</title>
          <description>Propofol-remifentanil Bupivacaine; Lidocaine Epinephrine (with local anaesthetics for skin infiltration)&#xD;
Remifentanil: Remifentanil used for conscious sedation.&#xD;
Propofol: Used for conscious sedation.&#xD;
Bupivacaine: Local anaesthetics&#xD;
Lidocaine: Local anaesthetic&#xD;
Epinephrine: With local anaesthetic for skin infiltration.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="30"/>
            <count group_id="B2" value="30"/>
            <count group_id="B3" value="60"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32.5" spread="10.5"/>
                    <measurement group_id="B2" value="33.4" spread="10.5"/>
                    <measurement group_id="B3" value="33" spread="10.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="27"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Egypt</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Patients Satisfaction</title>
        <description>Patient's satisfaction was recorded using a score ranging from 0 for not satisfied to 10 for totally satisfied.</description>
        <time_frame>1 hour after the operation</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Conscious sedation1</title>
            <description>Propofol-dexmedetomidine Bupivacaine; Lidocaine (local anaesthetics) Epinephrine (with local anaesthetics for skin infiltration)&#xD;
Dexmedetomidine: Dexmedetomidine used for conscious sedation.&#xD;
Propofol: Used for conscious sedation.&#xD;
Bupivacaine: Local anaesthetics&#xD;
Lidocaine: Local anaesthetic&#xD;
Epinephrine: With local anaesthetic for skin infiltration.</description>
          </group>
          <group group_id="O2">
            <title>Conscious sedation2</title>
            <description>propofol-remifentanil Bupivacaine; Lidocaine Epinephrine (with local anaesthetics for skin infiltration)&#xD;
Remifentanil: Remifentanil used for conscious sedation.&#xD;
Propofol: Used for conscious sedation.&#xD;
Bupivacaine: Local anaesthetics&#xD;
Lidocaine: Local anaesthetic&#xD;
Epinephrine: With local anaesthetic for skin infiltration.</description>
          </group>
        </group_list>
        <measure>
          <title>Patients Satisfaction</title>
          <description>Patient's satisfaction was recorded using a score ranging from 0 for not satisfied to 10 for totally satisfied.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.33" spread="1.36"/>
                    <measurement group_id="O2" value="6.45" spread="1.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>During the operation, on average 3 hours.</time_frame>
      <desc>Apnea and airway obstruction.</desc>
      <group_list>
        <group group_id="E1">
          <title>Propofol-dexmedetomidine</title>
          <description>Propofol-dexmedetomidine Bupivacaine; Lidocaine (local anaesthetics) Epinephrine (with local anaesthetics for skin infiltration)&#xD;
Dexmedetomidine: Dexmedetomidine used for conscious sedation.&#xD;
Propofol: Used for conscious sedation.&#xD;
Bupivacaine: Local anaesthetics&#xD;
Lidocaine: Local anaesthetic&#xD;
Epinephrine: With local anaesthetic for skin infiltration.</description>
        </group>
        <group group_id="E2">
          <title>Propofol-remifentanil</title>
          <description>Propofol-remifentanil Bupivacaine; Lidocaine Epinephrine (with local anaesthetics for skin infiltration)&#xD;
Remifentanil: Remifentanil used for conscious sedation.&#xD;
Propofol: Used for conscious sedation.&#xD;
Bupivacaine: Local anaesthetics&#xD;
Lidocaine: Local anaesthetic&#xD;
Epinephrine: With local anaesthetic for skin infiltration.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Professor Ezzeldin Ibrahim, Professor of Anaesthesia</name_or_title>
      <organization>Menoufia University</organization>
      <phone>00201006303178</phone>
      <email>ezzeldin7@yahoo.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

